TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12160589

Group type: EXPERIMENTAL
Intervention: BCG instillations alone
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Alternating instillations of interferon‐alpha and BCG monthly for up to 1 year
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) instillations
Number of subjects: 205

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 205
Study: 10574555

Group type: EXPERIMENTAL
Intervention: High contrast condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low contrast condition
Number of subjects: 0
Study: 7600834

Group type: EXPERIMENTAL
Intervention: Microwave warming of packed RBCs
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Countercurrent water bath warming of packed RBCs
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Microwave heating cartridge
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Countercurrent heat exchanger
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: In-line microwave device
Number of subjects: 24

Group type: COMPARATOR
Intervention: Countercurrent water bath warming
Number of subjects: 24
Study: 2223346

Group type: EXPERIMENTAL
Intervention: Ohmeda 3700
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nellcor N100
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nellcor N200
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Datex Oscar
Number of subjects: 0

Group type: COMPARATOR
Intervention: Venous obstruction and cold-induced peripheral vasoconstriction
Number of subjects: 0
Study: 663698

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 263

Group type: COMPARATOR
Intervention: Control
Number of subjects: 263
Study: 31707329

Group type: EXPERIMENTAL
Intervention: Eastern European participants
Number of subjects: 1591

Group type: COMPARATOR
Intervention: North American participants
Number of subjects: 1591
Study: 27334464

Group type: EXPERIMENTAL
Intervention: Couples-focused HIV intervention program (27 couples) with 3 counseling sessions: 2 couples-focused sessions and 1 individual-focused session
Number of subjects: 112

Group type: COMPARATOR
Intervention: General HIV prevention information session (29 couples)
Number of subjects: 112
Study: 25220046

Group type: EXPERIMENTAL
Intervention: Weight reduction programme (group therapy with a 5-day educational intervention and five 2-hour follow-up visits)
Number of subjects: 124
Study: 25042661

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 155

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Hypertensive CoA
Number of subjects: 155
Study: 22971492

Group type: EXPERIMENTAL
Intervention: Extraperitoneal colostomy without damaging the muscle layer of the abdominal wall
Number of subjects: 128

Group type: COMPARATOR
Intervention: Conventional colostomy
Number of subjects: 128
Study: 19236549

Group type: EXPERIMENTAL
Intervention: 1-pot test product (fermented milk containing Bifidobacterium lactis DN-173010)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: 2-pot test product (fermented milk containing Bifidobacterium lactis DN-173010)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Control group (usual diet)
Number of subjects: 371
Study: 17870161

Group type: EXPERIMENTAL
Intervention: Expert-assisted case management
Number of subjects: 80

Group type: COMPARATOR
Intervention: Case management as usual
Number of subjects: 80
Study: 15081141

Group type: EXPERIMENTAL
Intervention: Riboflavin-containing microballoons (MB) administered orally
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Riboflavin-containing microballoons (MB) with particle size: 500-1000 microm
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Riboflavin-containing microballoons (MB) mixed with hydroxypropylmethylcellulose (HPMC)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Riboflavin-containing microballoons (MB)
Number of subjects: 3
Study: 12171452

Group type: EXPERIMENTAL
Intervention: Calcium supplement containing 1,000 mg supplemental calcium as calcium citrate malate (n=7)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo of methylcellulose (n=9)
Number of subjects: 16
Study: 9255524

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Endoscopic variceal sclerotherapy (EVS)
Number of subjects: 111
Study: 8105778

Group type: EXPERIMENTAL
Intervention: Group treatment with cognitive therapy followed by exposure in vivo
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Exposure in vivo
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Integrated treatment (cognitive-behavioral treatment)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Waiting-list period (control)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 73
Study: 3802928

Group type: EXPERIMENTAL
Intervention: Diltiazem (0.2, 0.3, and 0.4 mg/kg body weight, followed by infusion of 2, 3, and 4 micrograms/kg/min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31695323

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.1 µg/kg/h)
Number of subjects: 557

Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline)
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 557
Study: 29752923

Group type: EXPERIMENTAL
Intervention: Video-based contraceptive education
Number of subjects: 240

Group type: COMPARATOR
Intervention: Conversational counseling
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Both groups (video and conversational)
Number of subjects: 240
Study: 26611473

Group type: EXPERIMENTAL
Intervention: Rituximab added to fludarabine and cyclophosphamide chemotherapy
Number of subjects: 370
Study: 24691332

Group type: EXPERIMENTAL
Intervention: Access to the online training resource (Microsurgery Essentials)
Number of subjects: 17

Group type: COMPARATOR
Intervention: No access to the online training resource
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Self-confidence in residents
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Experience level of residents
Number of subjects: 17
Study: 22390448

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention care (IC)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 312
Study: 20399952

Group type: EXPERIMENTAL
Intervention: Buccal misoprostol (200 mcg every 6 hours after initial 400 mcg vaginally)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Vaginal misoprostol (initial 400 mcg, then 200 mcg every 6 hours)
Number of subjects: 64
Study: 17613583

Group type: EXPERIMENTAL
Intervention: Combination of calcium/vitamin D supplements and exercise/protein
Number of subjects: 24

Group type: COMPARATOR
Intervention: Calcium/vitamin D supplements
Number of subjects: 24
Study: 16236107

Group type: COMPARATOR
Intervention: PCC (plasma-derived prothrombin concentrates)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HPFIX (high purity FIX concentrate)
Number of subjects: 12
Study: 12844328

Group type: EXPERIMENTAL
Intervention: Subcutaneous melagatran
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Oral ximelagatran
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Individualised dosage based on creatinine clearance or bodyweight
Number of subjects: 216
Study: 11095442

Group type: EXPERIMENTAL
Intervention: Alendronate treatment for 3-4 years
Number of subjects: 3658
Study: 8720425

Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg extended-release (ER)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1304448

Group type: EXPERIMENTAL
Intervention: Moclobemide 150 mg t.i.d.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo t.i.d.
Number of subjects: 24
Study: 3934968

Group type: EXPERIMENTAL
Intervention: melphalan/prednisone
Number of subjects: 101

Group type: COMPARATOR
Intervention: colchicine
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: melphalan/prednisone (only regimen)
Number of subjects: 101

Group type: COMPARATOR
Intervention: colchicine (only regimen)
Number of subjects: 101
Study: 3113974

Group type: EXPERIMENTAL
Intervention: Growth hormone releasing factor (hGRF-44 NH2) administered intravenously at doses of 2.5-80 micrograms, 80-320 micrograms, and 75-600 micrograms
Number of subjects: 0
Study: 31219706

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with a median dose of 42 Gy/6 fractions (range 25 - 54 Gy/6#)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 21
Study: 28350537

Group type: EXPERIMENTAL
Intervention: Structured Physical Activity (SPA)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Unstructured Physical Activity (USPA)
Number of subjects: 439
Study: 26444882

Group type: EXPERIMENTAL
Intervention: Nipple stimulation
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Uterine stimulation
Number of subjects: 390

Group type: COMPARATOR
Intervention: Control
Number of subjects: 390
Study: 22762307

Group type: EXPERIMENTAL
Intervention: High thoracic epidural analgesia (HTEA)
Number of subjects: 42
Study: 21574673

Group type: EXPERIMENTAL
Intervention: Religious salience growth factors
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Religious attendance growth factors
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Family intervention
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Thrill seeking
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Early adolescent substance use
Number of subjects: 667
Study: 19485591

Group type: EXPERIMENTAL
Intervention: One-session exposure treatment
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Education support treatment
Number of subjects: 196

Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 196
Study: 17229902

Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 43
Study: 15590533

Group type: EXPERIMENTAL
Intervention: Anticoagulant/antiaggregating agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Troxerutin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticosteroid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fibrinolytic/thrombolytic agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemodilution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medical management of RVO
Number of subjects: 0
Study: 10939703

Group type: EXPERIMENTAL
Intervention: Ammonium sulphate 10% plus lidocaine 1%
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lidocaine 1%
Number of subjects: 12
Study: 9399311

Group type: EXPERIMENTAL
Intervention: Feedback on speed of throwing
Number of subjects: 26

Group type: COMPARATOR
Intervention: Feedback on accuracy of throwing
Number of subjects: 26
Study: 8173688

Group type: EXPERIMENTAL
Intervention: Felodipine-Metoprolol combination tablet
Number of subjects: 186

Group type: COMPARATOR
Intervention: Felodipine
Number of subjects: 186

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 186
Study: 3766838

Group type: EXPERIMENTAL
Intervention: Nursing follow-up services
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no nursing follow-up)
Number of subjects: 0
Study: 31634450

Group type: EXPERIMENTAL
Intervention: Active iTBS over the left DLPFC
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham iTBS over the left DLPFC
Number of subjects: 14
Study: 30355865

Group type: EXPERIMENTAL
Intervention: Aurolab aqueous drainage implant (AADI)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Ahmed glaucoma valve (AGV)
Number of subjects: 38
Study: 27203715

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg daily
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 24025111

Group type: EXPERIMENTAL
Intervention: Sodium valproate 500 mg daily (or 400 mg daily by intravenous infusion) for 7 days
Number of subjects: 258

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 258
Study: 22858044

Group type: EXPERIMENTAL
Intervention: 0.1% bupivacaine 10 mL and morphine 1.5mg (Group B+Mor)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 0.1% bupivacaine 10 mL and magnesium 500 mg (Group B+Mg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 0.1% bupivacaine 10 mL morphine 1.5mg and magnesium 500 mg (Group B+Mor+Mg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 0.1% bupivacaine 10 mL (Group B)
Number of subjects: 200
Study: 20181257

Group type: EXPERIMENTAL
Intervention: Restrictive intraoperative intravenous fluid administration (Group A)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Liberal intraoperative intravenous fluid administration (Group B)
Number of subjects: 192
Study: 18664153

Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser (PDL)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Light-Emitting Diode (LED)
Number of subjects: 45
Study: 16451383

Group type: EXPERIMENTAL
Intervention: ADS rinse 1
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: ADS rinse 2
Number of subjects: 3

Group type: COMPARATOR
Intervention: Positive control rinse
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 3
Study: 28555207

Group type: EXPERIMENTAL
Intervention: Immediate implant installation in fresh extraction sockets grafted with cortico‐cancellous heterologous bone and porcine derma (group A)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Delayed implant installation 4 months after tooth extraction and socket preservation using the same materials (group B)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Immediate implant installation (group A)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Delayed implant installation (group B)
Number of subjects: 24
Study: 10717755

Group type: EXPERIMENTAL
Intervention: Chloroquine plus 5-days primaquine
Number of subjects: 350

Group type: COMPARATOR
Intervention: Chloroquine alone
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Chloroquine plus 14-days primaquine
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Chloroquine 25 mg/kg and 14-days primaquine
Number of subjects: 350
Study: 7745511

Group type: EXPERIMENTAL
Intervention: Synthetic surfactant (Exosurf Neonatal)
Number of subjects: 597

Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 597
Study: 1971516

Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg once daily
Number of subjects: 285

Group type: COMPARATOR
Intervention: Cetirizine 10 mg once daily
Number of subjects: 285
Study: 7025876

Group type: EXPERIMENTAL
Intervention: Meptazinol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 20
Study: 30512084

Group type: EXPERIMENTAL
Intervention: Primary cervical HPV testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cytology testing
Number of subjects: 0
Study: 26568203

Group type: EXPERIMENTAL
Intervention: 5 sets of 8 repetitions with 3 min of rest between sets (8S)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 10 sets of 4 repetitions with 80 s of rest between sets (4S)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 40 sets of 1 repetition with 18.5 s of rest between each repetition (1S)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control session (not specified)
Number of subjects: 17
Study: 25270857

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.5 μg/kg bolus over 60 s followed by 0.05 μg/kg/min continuous infusion for 20 min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (0.9% sodium chloride infusion at a volume and rate equal to that of remifentanil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study: 22357846

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 27

Group type: COMPARATOR
Intervention: Atomoxetine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 27
Study: 20585896

Group type: EXPERIMENTAL
Intervention: Gain-framed message (describing benefits of receiving the vaccine)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Loss-framed message (describing costs of not receiving the vaccine)
Number of subjects: 72
Study: 16930145

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis with a single dose of amoxicillin and clavulanic acid (group A, n = 193)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Placebo (group B, n = 193)
Number of subjects: 386
Study: 15848701

Group type: EXPERIMENTAL
Intervention: Alemtuzumab induction (30 mg IV intraoperatively) with rapid corticosteroid elimination
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group with alternate day rabbit antithymocyte globulin (rATG) induction with a steroid-based regimen
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Alemtuzumab induction
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Alemtuzumab group
Number of subjects: 32
Study: 12486437

Group type: EXPERIMENTAL
Intervention: Nesiritide (0.015 or 0.03 microg/kg/min)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Dobutamine (>=5 microg/kg/min)
Number of subjects: 255
Study: 10354696

Group type: EXPERIMENTAL
Intervention: Rehabilitation (R)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Oxygen therapy (T)
Number of subjects: 21
Study: 8073235

Group type: EXPERIMENTAL
Intervention: Insurance supplement for unconventional medicine (experimental group)
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Self-selected insurance supplement for unconventional medicine (third group)
Number of subjects: 5000

Group type: COMPARATOR
Intervention: No coverage of unconventional medicine (control group)
Number of subjects: 5000
Study: 2645662

Group type: EXPERIMENTAL
Intervention: Top-up transfusions to keep haemoglobin concentrations above 10 g/dl
Number of subjects: 20

Group type: COMPARATOR
Intervention: No transfusions, allowing haemoglobin concentrations to fall below 10 g/dl
Number of subjects: 20
Study: 29768301

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with bevacizumab (457 patients, 128 achieved pCR)
Number of subjects: 920

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy without bevacizumab
Number of subjects: 920
Study: 25482371

Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) 1800mg day(-1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Metformin (MET) 1500mg day(-1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) 1800mg day(-1) + Metformin (MET) 1500mg day(-1)
Number of subjects: 60
Study: 24081186

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (25 IU/day for 60 days)
Number of subjects: 65
Study: 21695594

Group type: EXPERIMENTAL
Intervention: Health Survey Short Form (SF‐36)
Number of subjects: 3622

Group type: EXPERIMENTAL
Intervention: Two-week Morbidity Rate
Number of subjects: 3622

Group type: EXPERIMENTAL
Intervention: Job Satisfaction
Number of subjects: 3622

Group type: EXPERIMENTAL
Intervention: Multiple stepwise linear regression analysis
Number of subjects: 3622

Group type: EXPERIMENTAL
Intervention: Digestive system disease
Number of subjects: 3622

Group type: EXPERIMENTAL
Intervention: Urinary system disease
Number of subjects: 3622

Group type: EXPERIMENTAL
Intervention: Gynecological disease
Number of subjects: 3622
Study: 19590244

Group type: EXPERIMENTAL
Intervention: Lutein
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 20
Study: 17900691

Group type: EXPERIMENTAL
Intervention: Laser peripheral iridotomy (LPI) in one eye
Number of subjects: 205
Study: 15799724

Group type: EXPERIMENTAL
Intervention: Transpupillary thermotherapy (TTT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 28
Study: 12772546

Group type: EXPERIMENTAL
Intervention: Diabetes self-management program
Number of subjects: 109

Group type: COMPARATOR
Intervention: Delayed intervention (control group)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Participants recruited from FBOs
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Participants recruited from health system
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Participants recruited from community
Number of subjects: 109

Group type: COMPARATOR
Intervention: Participants recruited from FBOs (control)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Participants recruited from health system (control)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Participants recruited from community (control)
Number of subjects: 109
Study: 9275269

Group type: EXPERIMENTAL
Intervention: Prostate specific antigen prescreening followed by digital rectal examination, transrectal ultrasound, and biopsy if indicated.
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Prostate specific antigen prescreening only (no additional screening).
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Information materials and invitation procedures.
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Single prostate specific antigen determination.
Number of subjects: 1000
Study: 1773136

Group type: EXPERIMENTAL
Intervention: AHBuBP (5 mg/day on two consecutive days every 3 months for one year)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Calcium (oral)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: AHBuBP
Number of subjects: 40
Study: 7265072

Group type: EXPERIMENTAL
Intervention: Oestrogen replacement
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 31095119

Group type: EXPERIMENTAL
Intervention: Nonpharmacologic interventions for chronic low back pain
Number of subjects: 10

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10
Study: 29259055

Group type: EXPERIMENTAL
Intervention: Hughes repair
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard mass closure
Number of subjects: 30
Study: 26341174

Group type: EXPERIMENTAL
Intervention: 1 g tranexamic acid
Number of subjects: 200

Group type: COMPARATOR
Intervention: 5% glucose (placebo)
Number of subjects: 200
Study: 24355417

Group type: EXPERIMENTAL
Intervention: Resourcefulness training (RT), a cognitive-behavioral intervention, delivered over a 6 week study period.
Number of subjects: 0
Study: 21919984

Group type: EXPERIMENTAL
Intervention: Methotrexate administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no methotrexate)
Number of subjects: 0